Research Progress and Clinical Prospects of Dendritic Cell Vaccines in Breast Cancer Immunotherapy
DOI:
https://doi.org/10.61173/ty1wsm47Keywords:
-Immunotherapy, breast cancer, dendritic cell vaccine, tumor microenvironment, antigen presentationAbstract
Dendritic cell (DC) vaccines have shown significant research progress and clinical prospects in breast cancer immunotherapy. This article seeks to explain how dendritic cells (DC) show antigens in the immune environment of breast cancer and discuss the difficulties in creating and preparing DC vaccines to make them more effective. The advantages and disadvantages of DC vaccinations and other therapies were evaluated, combined application strategy of DC vaccines with other therapies such chemotherapy, immune checkpoint inhibitors, and radiotherapy was examined. By improving Presentation of an antigen and reducing T cell immunosuppression, the data demonstrated that DC vaccines can have a synergistic effect when used in conjunction with other treatments, greatly boosting the immune system that combats tumors. response. Compared with CAR-T cell therapy, DC vaccines are less likely to cause serious side effects such as cytokine storms. Compared with PD-L1 inhibitors, DC vaccines can actively activate the immune system, produce immune responses against specific tumor antigens, and have immune memory effects. To further enhance the design and administration of DC vaccines and increase their effectiveness in breast cancer immunotherapy, future research should concentrate on the creation of novel vaccine adjuvants, The discovery of new antigens related to tumors and the development of vaccine delivery methods.
References
[1] M. Arnold, E. Morgan, H. Rumgay, et al., “Current and future burden of breast cancer: Global statistics for 2020 and 2040,” Breast, vol. 66, pp. 15–23, Dec. 2022.
[2] J. Ni, J. Song, B. Wang, et al., “Dendritic cell vaccine for the effective immunotherapy of breast cancer,” Biomed. Pharmacother., vol. 126, p. 110046, Jun. 2020.
[3] Z. Liu, X. Yu, L. Xu, et al., “Current insight into the regulation of PD-L1 in cancer,” Exp. Hematol. Oncol., vol. 11, no. 1, p. 44, Jul. 2022.
[4] Y. C. Chien, J. Y. Wu, L. C. Liu, et al., “Capsanthin inhibits migration and reduces N-linked glycosylation of PD-L1 via the EZH2-PD-L1 axis in triple-negative breast cancer brain metastasis,” Cell Death Discov., vol. 11, no. 1, p. 85, Mar. 2025.
[5] P. Liu, L. Zhao, G. Kroemer, et al., “Conventional type 1 dendritic cells (cDC1) in cancer immunity,” Biol. Direct, vol. 18, p. 71, 2023.
[6] H. Soliman, A. Aldrich, N. Abdo, et al., “A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER− breast cancer,” npj Breast Cancer, vol. 11, p. 29, 2025.
[7] I. Heras-Murillo, D. Mañanes, P. Munné, et al., “Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse,” Nat. Commun., vol. 16, p. 3369, 2025.
[8] M. Santisteban, B. P. Solans, L. Hato, et al., “Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients: clinical and translational analysis,” Ther. Adv. Med. Oncol., vol. 13, p. 17588359211064653, Dec. 2021.
[9] S. Zhang, M. Chopin, S. L. Nutt, “Type 1 conventional dendritic cells: ontogeny, function, and emerging roles in cancer immunotherapy,” Trends Immunol., vol. 42, no. 12, pp. 1113– 1127, Dec. 2021.
[10] L. Gelao, C. Criscitiello, A. Esposito, et al., “Dendritic cell-based vaccines: clinical applications in breast cancer,” Immunotherapy, vol. 6, no. 3, pp. 349–360, 2014.
[11] H. Lee, H. J. Lee, I. H. Song, et al., “CD11c-Positive Dendritic Cells in Triple-negative Breast Cancer,” In Vivo, vol. 32, no. 6, pp. 1561–1569, Nov.–Dec. 2018.
[12] Y. Ge, H. Xi, S. Ju, et al., “Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice,” Cancer Lett., vol. 336, no. 2, pp. 253–259, Aug. 2013.
[13] A. I. Sebastião, G. Simões, F. Oliveira, et al., “Dendritic cells in triple-negative breast cancer: From pathophysiology to therapeutic applications,” Cancer Treat. Rev., vol. 133, p. 102884, Feb. 2025.
[14] V. Bandara, J. Foeng, B. GunDCambuu, et al., “Pre-clinical validation of a pan-cancer CAR-T cell immunotherapy targeting nfP2X7,” Nat. Commun., vol. 14, no. 1, p. 5546, Sep. 2023.
[15] M. V. Dhodapkar, M. Sznol, B. Zhao, et al., “Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205,” Sci. Transl. Med., vol. 6, no. 232, p. 232ra51, Apr. 2014.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
